LungLife AI Valuation

Is 9H4 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 9H4 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 9H4's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 9H4's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 9H4?

Key metric: As 9H4 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 9H4. This is calculated by dividing 9H4's market cap by their current book value.
What is 9H4's PB Ratio?
PB Ratio	0.4x
Book	US$7.93m
Market Cap	US$3.47m

9H4 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	37x
Enterprise Value/EBITDA	-0.2x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does 9H4's PB Ratio compare to its peers?

The above table shows the PB ratio for 9H4 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	15.3x
T5O bioXXmed	13.2x	n/a	€1.4m
CNW co.don	1x	n/a	€6.5m
MDG1 Medigene	1x	11.0%	€20.6m
VSC 4SC	45.8x	n/a	€51.9m
9H4 LungLife AI	0.4x	101.0%	€2.8m

Price-To-Book vs Peers: 9H4 is good value based on its Price-To-Book Ratio (0.4x) compared to the peer average (20x).

Price to Book Ratio vs Industry

How does 9H4's PB Ratio compare vs other companies in the DE Biotechs Industry?

3 Companies	Price / Book	Estimated Growth	Market Cap
V9Z Aceragen	0.1x	n/a	US$3.12m
V9Z Aceragen	0.1x	n/a	US$2.18m
O7P NeuBase Therapeutics	0.1x	n/a	US$1.39m

No more companies available in this PB range

3 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: 9H4 is good value based on its Price-To-Book Ratio (0.4x) compared to the European Biotechs industry average (2.4x).

Price to Book Ratio vs Fair Ratio

What is 9H4's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

9H4 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	0.4x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 9H4's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Teva Pharmaceutical Industries

US$18.9b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEV

US$15.55

1.6%

73.9%

Pharming Group

€492.8m

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.

PHGN

€0.71

0.4%

-33.2%

Almirall

€1.8b

A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.

E2Z

€8.45

1.1%

2.9%